Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412620 | 0.90 | ALOX12 (0.65) | CYP19A1ALDH1A1PTPN1ALOX12MEN1 | |
| SCHEMBL12825176 | 0.90 | ALOX12 (0.65) | CYP19A1ALDH1A1PTPN1ALOX12MEN1 | |
| SCHEMBL678189 | 0.90 | ALOX12 (0.65) | CYP19A1ALDH1A1PTPN1ALOX12MEN1 | |
| SCHEMBL13640753 | 0.86 | PTPN1 (0.56) | CYP19A1ALDH1A1PTPN1ALOX12MEN1 | |
| SCHEMBL6142399 | 0.85 | CYP19A1 (0.65) | CYP19A1ALDH1A1PTPN1ALOX12MEN1 | |
| SCHEMBL30217542 | 0.84 | PTPN1 (0.57) | CYP19A1ALDH1A1PTPN1ALOX12MEN1 | |
| SCHEMBL17963719 | 0.84 | PTPN1 (0.57) | CYP19A1ALDH1A1PTPN1ALOX12MEN1 | |
| SCHEMBL14183128 | 0.84 | PTPN1 (0.52) | CYP19A1ALDH1A1PTPN1ALOX12MEN1 | |
| Dihydrobiochanin A SCHEMBL30217535 | 0.83 | ALOX12 (0.67) | CYP19A1ALDH1A1PTPN1ALOX12MEN1 | |
| SCHEMBL29737519 | 0.80 | TDP1 (0.53) | CYP19A1PTPN1ALOX12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579303-B2 | Compositions containing polysaccharides | DSM IP ASSETS B.V. (NL) | 2017-02-28 | — | — | US | disclosed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2013074059-A2 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | disclosed |
| EP-1853252-B1 | COMPOSITIONS CONTAINING POLYSACCHARIDES | DSM IP ASSETS BV (NL) | 2010-09-08 | — | — | EP | disclosed |
| US-20080193575-A1 | Compositions Containing Polysaccharides | DSM IP ASSETS B.V. (NL) | 2008-08-14 | — | — | US | disclosed |
| US-7326797-B2 | Manufacture of isoflavones | DSM IP ASSETS B.V. (NL) | 2008-02-05 | — | — | US | disclosed |
| EP-1523478-B1 | MANUFACTURE OF ISOFLAVONES | DSM IP ASSETS BV (NL) | 2007-12-12 | — | — | EP | disclosed |
| EP-1853252-A1 | COMPOSITIONS CONTAINING POLYSACCHARIDES | DSMIP Assets B.V. (NL) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087164-A1 | COMPOSITIONS CONTAINING POLYSACCHARIDES | DSM IP ASSETS B.V. (NL) | 2006-08-24 | — | — | WO | disclosed |
| US-20050256321-A1 | Manufacture of isoflavones | DSM IP ASSETS B.V. (NL) | 2005-11-17 | — | — | US | disclosed |
| EP-1523478-A2 | MANUFACTURE OF ISOFLAVONES | DSM IP Assets B.V. (NL) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004009576-A2 | MANUFACTURE OF ISOFLAVONES | DSM IP ASSETS B.V. (NL) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193575-A1 | Compositions Containing Polysaccharides | GLMN, GRN, GCG | CYP19A1 1037/4885ALDH1A1 4783/4885PTPN1 221/4885 |
| US-20140275224-A1 | CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION | CDA, DCTD, ADA | CYP19A1 2218/4885ALDH1A1 2191/4885PTPN1 4798/4885 |
| US-20050256321-A1 | Manufacture of isoflavones | HAAO, HAO2, CYP2F1 | CYP19A1 9/4885ALDH1A1 1856/4885PTPN1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.